Trials / Completed
CompletedNCT02874664
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Stemcentrx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate the effect of rovalpituzumab tesirine on cardiac ventricular repolarization in subjects with small cell lung cancer (SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rovalpituzumab Tesirine | Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC) |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-09-12
- Completion
- 2018-09-12
- First posted
- 2016-08-22
- Last updated
- 2018-09-24
Locations
15 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02874664. Inclusion in this directory is not an endorsement.